IPO

A new study reveals payment failures cost billions as customer patience runs out in minutes, creating a crisis for retail and hospitality brands.

After a strategic pivot reverses a year of decline, Allurion's preliminary results show new growth. All eyes are now on the FDA for its 'procedureless' gastric balloon.

Erasca reports promising early data for its pan-RAS inhibitor, ERAS-0015, showing tumor shrinkage at low doses and shaking up the competitive landscape.

The genomics leader posted a 41% revenue surge in 2025 and projects profitability, yet its stock tumbled on what some see as conservative 2026 guidance.

V2X secures a major contract under the MDA's SHIELD program, positioning it to shape the future of America's layered defense with advanced tech.

BioXcel Therapeutics is pushing its drug IGALMI® for home use, a move that could transform mental healthcare but carries significant financial and safety risks.

With a key FDA filing and pivotal data on the horizon, Pharvaris aims to redefine HAE treatment with its convenient, rapid-acting oral therapy.

Amid rising costs and market volatility, Malaysia's top SMEs are redefining success. The SME100 Awards reveal how innovation fuels their remarkable growth.

Vallourec's significant contract win for Shell's Orca project signals the enduring strategic value of Brazil's deepwater reserves and advanced tech.

A minor change in Collective Metals' $1.5M financing deal reveals the high stakes in its hunt for Canadian uranium. Here’s what it means for investors.

With a hefty war chest and a veteran leadership team, Bleichroeder Acquisition Corp. II launches its search for a high-growth tech company to take public.

Facing a Nasdaq delisting notice, social commerce firm Webuy Global has 45 days to devise a plan to fix its $2.1M stockholders' equity deficiency.

Following its acquisition by education giant Cogna, Vasta Platform is leaving the US stock market, signaling a major shift in Brazil's EdTech landscape.

Hong Kong's 3E Network completes a $2M financing round, fueling its strategic shift into the competitive global AI infrastructure market.

As Triumph Financial preps its Q4 2025 results, investors watch to see if its tech investments can deliver on high growth expectations amid a complex freight market.

The Chinese auto-tech firm regained Nasdaq's minimum bid price but still faces delisting over its low market value, setting up a critical hearing.

VCI Global's new Kuala Lumpur AI Lounge offers subscription access to NVIDIA's top GPUs, aiming to democratize AI and build a future of robotics.

After a decade of research, a promising drug for Fragile X syndrome enters a key trial, offering hope for the first-ever targeted treatment for the disorder.

Nasdaq-listed retailer iPower diversifies its balance sheet with Bitcoin and Ethereum, leveraging BitGo's regulated infrastructure for custody and trading.

Biotech firm Bright Minds Biosciences closes a massive $175M deal, fueling its race to develop novel drugs for epilepsy and rare neurological conditions.